New drug access for Tough-to-Treat MS
NCT ID NCT04540861
First seen Jan 09, 2026 · Last updated May 12, 2026 · Updated 15 times
Summary
This program provides access to the drug siponimod for adults with secondary progressive multiple sclerosis (SPMS) whose disease is still active and who have no other good treatment options. The goal is to help control the disease and slow progression. Patients must meet specific criteria and their doctor must request the drug from the sponsor.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.